HC Wainwright Predicts Lower Earnings for Atossa Genetics

Atossa Genetics Inc. (NASDAQ:ATOS) – Analysts at HC Wainwright dropped their Q1 2026 EPS estimates for shares of Atossa Genetics in a research report issued on Thursday, March 26th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn ($1.34) per share for the quarter, down from their prior estimate of ($1.20). HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Atossa Genetics’ current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Atossa Genetics’ Q2 2026 earnings at ($1.45) EPS, Q3 2026 earnings at ($1.03) EPS, Q4 2026 earnings at ($1.07) EPS, FY2026 earnings at ($4.75) EPS, FY2027 earnings at ($0.61) EPS, FY2028 earnings at ($0.40) EPS and FY2029 earnings at ($0.20) EPS.

Other analysts have also recently issued research reports about the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Atossa Genetics in a report on Wednesday, January 21st. Ascendiant Capital Markets upped their price objective on shares of Atossa Genetics from $116.25 to $120.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $68.33.

Atossa Genetics Stock Down 0.2%

Atossa Genetics stock opened at $4.71 on Monday. The stock has a market cap of $40.55 million, a price-to-earnings ratio of -1.31 and a beta of 1.42. The business has a 50-day simple moving average of $5.62 and a 200 day simple moving average of $9.85. Atossa Genetics has a 52 week low of $3.76 and a 52 week high of $19.35.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. &PARTNERS bought a new position in Atossa Genetics in the fourth quarter valued at $25,000. Hudson Bay Capital Management LP bought a new stake in Atossa Genetics during the second quarter worth about $26,000. Gallagher Capital Advisors LLC bought a new stake in Atossa Genetics during the third quarter worth about $27,000. JPMorgan Chase & Co. boosted its holdings in shares of Atossa Genetics by 1,294.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock worth $33,000 after purchasing an additional 35,474 shares in the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of Atossa Genetics by 55.7% in the 2nd quarter. Bank of America Corp DE now owns 99,601 shares of the company’s stock worth $83,000 after purchasing an additional 35,629 shares in the last quarter. 12.74% of the stock is currently owned by hedge funds and other institutional investors.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.